Semaglutide vs Tirzepatide: Research Evidence and Key Differences
Semaglutide and tirzepatide are two important medicines in modern metabolic research. Both have been studied for type 2 diabetes and body-weight outcomes, but they differ in receptor activity and in the evidence generated by their clinical development programmes.
Earlier comparisons often relied on separate trials, making it difficult to determine whether differences in reported outcomes reflected the medicines themselves or differences in study design. More recent direct-comparison research provides additional evidence. Understanding these distinctions helps researchers evaluate efficacy, safety, cardiovascular outcomes, and the limits of current findings.
1. The Main Scientific Difference
Semaglutide and tirzepatide affect overlapping metabolic pathways, but their receptor targets differ.
Semaglutide: GLP-1 receptor agonist
Semaglutide activates the glucagon-like peptide-1 (GLP-1) receptor. Research has examined its effects on glucose-dependent insulin secretion, glucagon regulation, appetite-related signaling, and body weight.
Its clinical evidence includes randomized trials in type 2 diabetes, obesity, cardiovascular outcomes, and chronic kidney disease in specific populations.
Tirzepatide: dual GIP and GLP-1 receptor agonist
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. Researchers have investigated whether this dual activity produces different effects on glycemic control, body weight, and other metabolic outcomes.
The two-target mechanism distinguishes tirzepatide from semaglutide, but receptor activity alone does not establish comparative clinical value. That requires evidence from appropriately designed trials.
2. Direct Comparison in Type 2 Diabetes: SURPASS-2
The SURPASS-2 trial, published in The New England Journal of Medicine in 2021, directly compared tirzepatide with semaglutide in adults with type 2 diabetes.
The 40-week, open-label Phase 3 trial enrolled 1,879 participants. Tirzepatide was studied at 5 mg, 10 mg, and 15 mg, while the semaglutide comparator was 1 mg. The primary endpoint was the change in glycated hemoglobin (HbA1c), a measure of average blood glucose over the preceding months.
The study found that all three tirzepatide groups achieved greater average reductions in HbA1c than the semaglutide group. Mean body-weight reductions were also greater in the tirzepatide groups.
This is useful direct-comparison evidence because both medicines were evaluated within the same trial, using the same eligibility criteria and follow-up period. However, the findings apply to the specific doses and population studied. They should not be generalized automatically to other formulations, indications, or treatment regimens.
The trial was also open-label, meaning participants and investigators knew which treatment was assigned. That feature should be considered when evaluating outcomes that could be influenced by expectations or treatment behavior.
Source: .
3. Direct Comparison in Obesity: SURMOUNT-5
A particularly important development was the SURMOUNT-5 trial, published in The New England Journal of Medicine in May 2025.
Unlike studies that compare results across separate trials, SURMOUNT-5 directly compared tirzepatide with semaglutide in adults with obesity who did not have type 2 diabetes.
The Phase 3b trial randomized 751 participants to receive their maximum tolerated dose of tirzepatide, 10 mg or 15 mg, or semaglutide, 1.7 mg or 2.4 mg. Treatment continued for 72 weeks. The primary endpoint was percentage change in body weight.
The study reported these mean changes at week 72:
| Outcome | Tirzepatide | Semaglutide |
|---|---|---|
| Mean body-weight change | −20.2% | −13.7% |
| Mean waist-circumference change | −18.4 cm | −13.0 cm |
Tirzepatide produced a greater average reduction in body weight and waist circumference in this trial. The differences were statistically significant. Gastrointestinal adverse events were the most common in both groups, and most were mild to moderate and occurred mainly during dose escalation.
What makes SURMOUNT-5 different?
The trial offers stronger comparative evidence for its specific research question than a simple comparison of unrelated studies. Both treatments were evaluated within one randomized protocol, which reduces uncertainty caused by differences in trial populations and procedures.
However, several limitations remain important:
- The study was open-label.
- Participants did not have type 2 diabetes, so results should not be transferred directly to diabetes populations.
- The trial compared specified maximum tolerated doses, not every available formulation or regimen.
- The 72-week results do not resolve every question about long-term outcomes.
The most defensible conclusion is that tirzepatide produced greater average weight reduction than semaglutide under the conditions of SURMOUNT-5. It does not establish that tirzepatide is superior for every clinical outcome or every population.
Source: .
4. Why Separate Trials Can Produce Misleading Comparisons
Before direct-comparison evidence became available, discussions frequently contrasted the SURMOUNT-1 tirzepatide trial with the STEP 1 semaglutide trial.
SURMOUNT-1 reported mean body-weight changes of −15.0%, −19.5%, and −20.9% for tirzepatide at 5 mg, 10 mg, and 15 mg, respectively, compared with −3.1% for placebo at week 72.
STEP 1 reported a mean reduction of −14.9% with semaglutide and −2.4% with placebo at week 68.
Although these numbers are informative, the trials differed in their duration, participant characteristics, treatment protocols, and other methodological details. Comparing the largest percentage from one study with the result from another cannot establish comparative superiority.
Direct trials such as SURMOUNT-5 help address this limitation by evaluating treatments within a common protocol. Researchers should still examine the trial’s population, endpoints, and statistical methods before extending the conclusions beyond its scope.
Sources: and .
5. Cardiovascular Evidence: A Different Research Question
Body-weight reduction and cardiovascular risk reduction are related research areas, but they are not interchangeable endpoints.
Semaglutide has evidence from the SELECT trial, which evaluated major cardiovascular events in adults with established cardiovascular disease and overweight or obesity who did not have diabetes. The trial reported fewer primary composite cardiovascular events in the semaglutide group than in the placebo group.
Tirzepatide has also undergone dedicated cardiovascular outcomes research. In SURPASS-CVOT, published in December 2025, researchers compared tirzepatide with dulaglutide in people with type 2 diabetes and established atherosclerotic cardiovascular disease.
The primary endpoint combined cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Tirzepatide was found to be noninferior to dulaglutide for that endpoint, but the trial did not establish statistical superiority.
These studies cannot be used as a direct cardiovascular comparison between semaglutide and tirzepatide. They used different comparators and trial designs, and they studied defined populations.
Researchers should distinguish evidence for reducing body weight from evidence for reducing major cardiovascular events. One outcome cannot automatically establish the other.
Sources: and .
6. Safety and Tolerability Findings
Both medicines have been associated with gastrointestinal adverse events in clinical trials, including nausea, diarrhea, vomiting, and constipation. The frequency and severity of events depend on the study population, treatment regimen, follow-up period, and how adverse events are defined and recorded.
When comparing safety findings, researchers should examine:
- The proportion of participants experiencing any adverse event.
- Serious adverse events and whether investigators considered them treatment-related.
- The number of participants who discontinued treatment because of adverse events.
- The duration of follow-up and the completeness of safety reporting.
- Differences between the trial populations and treatment protocols.
A higher or lower event rate in one study does not automatically establish that one medicine is safer than the other. Even direct-comparison trials may be too short or too small to characterize rare or long-term outcomes fully.
Safety should therefore be evaluated alongside efficacy, rather than treated as a secondary detail beneath a headline result.
7. What Researchers Still Need to Investigate
Despite substantial clinical evidence, important questions remain across both medicines.
Long-term outcomes: Longer follow-up can help characterize durability of effects and outcomes that may not emerge during shorter trials.
Treatment discontinuation: Research into outcomes after treatment stops can clarify how body weight and other measures change over time.
Different populations: Findings from adults with obesity without diabetes may not apply directly to people with diabetes or other specific health conditions.
Cardiovascular and kidney outcomes: These endpoints require dedicated evidence in the populations being studied. Changes in weight or HbA1c alone cannot answer every question.
Body composition: Researchers continue to investigate how changes in total body weight relate to fat mass, lean mass, and functional outcomes.
Comparative safety: Larger evidence sets and longer follow-up may improve understanding of less common events and differences between populations.
These questions illustrate why no single study can settle every comparison. Each result contributes to a wider evidence base that develops over time.
Frequently Asked Questions
Is tirzepatide more effective than semaglutide for weight reduction?
In SURMOUNT-5, tirzepatide produced greater average weight reduction than semaglutide over 72 weeks among adults with obesity without type 2 diabetes. That finding applies to the trial’s specific population, regimens, and endpoints.
What is the main difference between the two compounds?
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors. Their clinical effects must be evaluated through trial evidence rather than receptor activity alone.
Did SURPASS-2 compare the medicines directly?
Yes. SURPASS-2 compared tirzepatide at three doses with semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. The results favored tirzepatide for the study’s primary HbA1c endpoint and showed greater average weight reduction in the tirzepatide groups.
Does greater weight reduction prove better cardiovascular outcomes?
No. Body-weight change and cardiovascular events are different endpoints. Comparative cardiovascular conclusions require appropriate outcome trials and cannot be inferred from weight-loss results alone.
Are the two medicines supported by identical evidence?
No. They have overlapping but distinct clinical-development programmes, trial populations, formulations, and outcome data. Researchers should evaluate the evidence for each specific claim.
Conclusion
Semaglutide and tirzepatide share important metabolic research pathways but differ in receptor activity and clinical evidence. SURPASS-2 provides direct comparison evidence in type 2 diabetes, while SURMOUNT-5 found greater average weight reduction with tirzepatide than semaglutide in adults with obesity without diabetes.
These findings support specific conclusions about the trials studied, not universal claims about every outcome or population. Reliable comparisons require attention to study design, treatment regimens, safety, cardiovascular evidence, and remaining research gaps.
Research disclaimer: This article is for scientific and educational purposes only. It does not provide medical advice or recommend the purchase, use, or administration of any compound. Clinical findings should be evaluated using original peer-reviewed publications and current official regulatory information.